• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Grand Rounds

The DIETFITS Trial: Can Personal Genetics Determine Whether a Low-Fat or Low-Carb Diet is a Better Weight Loss Choice?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • While differences between low-fat and low-carbohydrate diets have been slight, there can be larger variability between those enrolled in a particular diet type
  • It has been suggested in previous literature that these differences could be related to
    • Underlying genetic make-up
    • Baseline Insulin dynamics such that individuals with greater insulin resistance may have better success with low-carbohydrate diets
  • Gardner et al. (JAMA 2018) examined the effect of healthy low-fat (HLF) diet vs a health low-carbohydrate(HLC) diet on weight change and if genotype pattern or insulin secretion are related to dietary effects on weight loss

METHODS:

  • Single-site, parallel-group, randomized trial
  • Data collected from The Diet Intervention Examining The Factors Interacting with Treatment Success (DIETFITS) trial
  • Participants: Patients 18 to 50 years without diabetes and body mass index between 28 and 40
  • Patients were randomized to 12 months of
    • HLF diet
    • HLC diet
  • Behavior modification intervention via 22 diet-specific small group sessions
    • Focused on ways to achieve the lowest fat or carbohydrate intake that could maintained over long periods of time
  • 3 SNPs (previously identified in weight loss studies) and INS-30 (blood concentration of insulin 30 minutes after a glucose challenge) were tested for association with weight loss
  • Primary outcome: 12-month weight change and determination of whether there were significant interactions among diet type and genotype pattern, diet and insulin secretion, and diet and weight loss

RESULTS:

  • Data was collected from 609 participants
    • Mean age, 40 years | 57% women | mean BMI, 33
    • 40% had a low-fat genotype and 30% had a low-carbohydrate genotype
    • Mean baseline INS-30, 93 μIU/mL
  • In the HLF vs HLC diets, respectively, the mean 12-month macronutrient distributions were 48% vs 30% for carbohydrates, 29% vs 45% for fat, and 21% vs 23% for protein
  • There was no significant difference in weight change at 12 months between the two groups
    • −5.3 kg for the HLF diet vs −6.0 kg for the HLC diet (mean between-group difference, 0.7 kg [95% CI, −0.2 to 1.6 kg])
  • There was no significant diet-genotype pattern interaction (P = .20) or diet-insulin secretion (INS-30) interaction (P = .47) with 12-month weight loss
  • Secondary Findings
    • Blood lipid results
      • HLF group: More favorable LDL cholesterol profile
      • HLC group: More favorable HDL cholesterol and triglyceride profile

CONCLUSION:

  • There was no significant change in weight loss between a healthy low-fat and low-carbohydrate diet
  • There was no significant interaction between genotype or insulin secretion with weight loss

Learn More – Primary Sources:

Effect of Low-Fat vs Low-Carbohydrate Diet on 12-Month Weight Loss in Overweight Adults and the Association With Genotype Pattern or Insulin Secretion

image_pdfFavoriteLoadingFavorite

< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

PURE Study Results – Carbs vs Fat Intake to Reduce Cardiovascular Morbidity and Mortality?
More From the PURE Study: Does Type of Exercise Matter When it Comes to Decreasing Mortality and CVD?  
Results of the DiRECT Trial: Can Weight Loss in a Primary Care Setting Achieve Remission of Type 2 Diabetes?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site